Trial · NCT07420439
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
NCT07420439, Phase 2, Not yet recruiting, Intergroupe Francophone de Cancerologie Thoracique
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease. Trials, record NCT07420439. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07420439
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
- NCT number
- NCT07420439
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 108 participants, estimated
- Lead sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Conditions
- Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)
- Interventions
- Paclitaxel, Bevacizumab, Carboplatin, Pemetrexed, Vinorelbine, Nivolumab, Pembrolizumab, Gemcitabine
- First posted
- 2026-02-19
- Last updated
- 2026-08-11
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 1st line part: disease Control Rate at 8 weeks | 8 weeks from date of inclusion | Assessed by investigators according to RECIST 1.1. |
| Primary | 2nd line part: Treatment related respiratory worsening leading to discontinuation of treatment during the first 6 months | 6 months from randomisation | |
| Secondary | Progression-free survival | About 6 months | |
| Secondary | Duration of response | About 6 months | |
| Secondary | Overall Survival | About 20 months | |
| Secondary | Best overall response | About 6 months | |
| Secondary | 1st line part: Disease control rate at 8 weeks | 8 weeks | Assessed by Independent Central Review |
| Secondary | 2nd line part: Disease control rate at 8 weeks | 8 weeks | Assessed by Investigators |
| Secondary | Progression-free survival according to ILDs pattern on CT scan | About 6 months | |
| Secondary | Duration of response according to ILDs pattern on CT scan | About 6 months |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07420439
GET https://conductscience.org/api/trials/v1/NCT07420439/registered?page=2